RXi Pharmaceuticals announced this month that its stock has once again begun trading on the Nasdaq stock market.
"Listing on Nasdaq will help us gain access to a broader institutional investment community and to provide greater liquidity for our shareholders," RXi President and CEO Geert Cauwenbergh said in a statement.
RXi had previously traded on the Nasdaq but lost its listing when it merged with Apthera in 2011. The new company changed its name to Galena, took RXi’s stock listing, and made RXi a subsidiary. RXi was later spun out as a publicly traded independent company again, but traded on the over-the-counter bulletin board.